Supreme Court denies W.L. Gore in stent graft patent spat with C.R. Bard

January 15, 2013 by MassDevice staff

The U.S. Supreme Court refuses to hear an appeal from W.L. Gore & Assoc. in a patent war with C.R. Bard over stent graft technology.

C.R. Bard logo
W.L. Gore & Associates logo

The U.S. Supreme Court dashed the last hopes of W.L. Gore & Assoc. in its long-running patent war with C.R. Bard (NYSE:BCR) over vascular graft technology.

Last October Gore asked the Supremes to consider its appeal of a $186 million patent loss to Bard.

Today the high court denied that bid, whereupon Bard promptly filed a motion to compel payment in the U.S. District Court for Arizona, according to a regulatory filing.

Sign up to get our free newsletters delivered straight to your inbox

Gore alleged that 1 of its engineers, Peter Cooper, invented a key claim in the patent in the early 1970s, according to a petition for a writ of certiorari filed with the high court.

Comments